Start
Features
Free trial / FAQ

Researchers
Physicians
Pharmacists
Ecotrophologists
Product Managers
in Health Industries

Loading…

Medical Research Finder

Legal Notice
Privacy
Terms of Use

meRfi® Microbiome - The Digital Gut Microbiome Reference (incl. AI Chat)
Prebiotics, Probiotics, FMT / Manipulators of the Intestinal Microbiota

AuthorsReferences (Sources)

meRfi® AI Chat

Obeticholic acid (OCA) & Non-alcoholic Steatohepatitis (NASH)

Welcome to meRfi Microbiome!

Please register to continue your trial period!

meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.

Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.

Start your free trial and transform your understanding of the gut microbiota today!

(Login)

Navigation

FXR agonist obeticholic acid (OCA) has recently been approved for treating primary biliary cholangitis and is being evaluated in phase-3 clinical trials for Non-alcoholic Steatohepatitis (NASH) treatment
Li & Chiang 2020 Hepatobiliary Surg. Nutr. 9: 152-169

Obeticholic acid 25 mg significantly improved fibrosis and key components of [Non-Alcoholic Steatohepatitis (NASH / MASH)](brain://GiE_VzTZS0mh705QAweeOQ/N…

References (Sources)

Bile acid-based therapies for non-alcoholic steatohepatitis and alcoholic liver disease
Li & Chiang 2020 Hepatobiliary Surg. Nutr. 9: 152-169
Review
Efficacy and safety of the farnesoid x receptor agonist obeticholic Acid in patients with type 2 diabetes and nonalcoholic Fatty liver disease
Mudaliar et al. 2013 Gastroenterology 145: 574-82
Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial
Neuschwander-Tetri et al. 2015 Lancet 385: 956-65
NASH and NAFLD: emerging drugs, therapeutic targets and translational and clinical challenges
Alkhouri 2020
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase III trial
Younossi et al. 2019 The Lancet 394: 2184-2196

AI Chat

7/1/2026

Chat with our artificial intelligence:

Start chat!

Obeticholic acid (OCA) & Non-alcoholic Steatohepatitis (NASH)

Welcome to meRfi Microbiome!

Navigation

Contents

References (Sources)

AI Chat